217 research outputs found
Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas.
Gut hormones that modulate the growth of normal pancreas may also modulate the growth of cancers originating from pancreas. This study visualized and compared the receptors for cholecystokinin (CCK), bombesin (BBS), secretin and vasoactive intestinal peptide (VIP) in tumour-free tissue sections of human pancreas (n = 10) and pancreatic ductal adenocarcinomas (n = 12) with storage phosphor autoradiography using radioligands. CCK-B receptors, present in control pancreata, were not detected in any of the pancreatic cancers. BBS receptors were visualized in control pancreata, but they were absent in 10 of 12 pancreatic cancers. In 5 of 12 pancreatic cancers, receptors for secretin were visualized, while binding for secretin was present in all tumour-free pancreata. Conversely, no specific binding of VIP was detected in control pancreata but was identified in 3 of 12 pancreatic cancer specimens. It is concluded that the expression of gut peptide receptors in pancreatic cancer differs from that in tumour-free pancreas. Receptors for these peptides are present in only a minority of pancreatic cancer specimens
Back to base pairs: what is the genetic risk for red bloodcell alloimmunization?
Red blood cell (RBC) alloimmunization is a serious complication of blood transfusions, challenging selection of compatible units for future transfusions. Genetic characteristics may be associated with the risk of RBC alloimmunization and may therefore serve to identify high-risk patients. The aim of this systematic review was to summarize the available evidence on genetic risk factors for RBC alloimmunization. Electronic databases were searched up to April 2020 for studies (Search terms included transfusion, alloimmunization and genetic). A total of 2581 alloimmunized cases and 26,558 controls were derived from 24 studies. The alleles that were most frequently studied and that demonstrated significant associations in a meta-analysis with alloimmunization to the Duffya antigen were HLA-DRB1*04 (Odds Ratio 7.80 (95%CI 4.57-13.33)), HLA-DRB1*15 (OR 3.76 (95%CI 2.14-6.59)), and HLA-DRB1*03 (OR 0.12 (95%CI 0.05-0.29)). Furthermore, significant associations with anti-K formation was found for the alleles HLA-DRB1*10 (OR 2.64 (95%CI 1.41-4.95)), HLA*DRB1*11 (OR 2.11, (95% CI 1.34-3.32)), and HLA-DRB1*13 (OR 1.71 (95%CI 1.26-2.33)). Overall, the available evidence was of moderate to low quality, hampering interpretation of reported results. There is an urgent need for high quality evidence on genetic risk factors for RBC alloimmunization
Gall-bladder dysmotility - A risk factor for gall-stone formation in hypertriglyceridaemia and reversal on triglyceride-lowering therapy with bezafibrate and fish oil
Doel: Onderzoeken van de pathofysiologische mechanismen die de kans op galstenen verhogen bij hypertriglyceridemie (HTG) en het vergelijken van de effecten van triglycerideverlagende therapie met bezafibraat en visolie op determinanten van cholelithiasis (biliaire lipidesamenstelling en galblaasmotoriek) bij HTG-patiënten.Opzet: Gekruiste opzet met ‘random’-volgorde.Patiënten en methoden: De galblaasmotoriek werd postprandiaal en tijdens cholecystokinine(CCK)-infusie echografisch onderzocht. De determinanten van cholelithiasis en de serumlipiden werden vergeleken tussen 9 HTG-patiënten en 10 normolipidemische controlepersonen van hetzelfde geslacht, dezelfde leeftijd en ‘body mass’-index. Bij de HTG-patiënten werden de effecten van bezafibraat en gezuiverde omega-3-olie (‘visolie’) bepaald.Resultaten: De serumtriglyceride(TG)-spiegel van de HTG-patiënten was 14-voudig verhoogd, vergeleken met de controlepersonen. De lipidesamenstelling van de gal, de nuchtere galblaasvolumen en de serum-CCK-spiegels verschilden niet tussen HTG-patiënten en controlepersonen. De galblaaslediging was verminderd bij HTG-patiënten versus controlepersonen tijdens CCK-infusie (–22) en ook na een maaltijd (–37; beide p < 0,001). De postprandiale serum-CCK-spiegels waren significant hoger bij HTG-patiënten. Zowel bezafibraat als visolie verlaagde de serum-TG-spiegel (–68 en –51 ten opzichte van de uitgangswaarde; beide: p < 0,01). Nuchtere CCK-spiegels verschilden niet, terwijl de CCK-geïnduceerde galblaaslediging onder bezafibraat toenam met 29 (p < 0,001) en met visolie met 13 (p = 0,07). De postprandiale galblaasmotoriek verbeterde tijdens zowel bezafibraat- (+47) als visoliebehandeling (+25; beide: p < 0,02), waarschijnlijk gedeeltelijk door een toegenomen gevoeligheid van de galblaas voor CCK (voor beide: p < 0,05 vergeleken met de uitgangsfase). Bezafibraat, in tegenstelling tot visolie, verhoogde de molaire cholesterol-galzuurratio (+40; p ≤ 0,05), terwijl beide behandelingen geen effect hadden op de cholesterolsaturatie-index.Conclusies: De verminderde galblaasmotoriek bij HTG-patiënten lijkt het gevolg te zijn van verminderde gevoeligheid voor CCK, wat kan bijdragen aan het verhoogde risico op galsteenvorming. Bij HTG-patiënten verbetert triglycerideverlagende therapie met visolie of bezafibraat de verminderde galblaasmotoriek zonder nadelig effect op de biliaire cholesterolverzadiging.Objective. To unravel the mechanisms responsible for the increased risk of gall-stone disease in hypertriglyceridaemia (HTG) and to compare the effects of triglyceride-lowering therapy with bezafibrate and fish oil on determinants of cholelithiasis (biliary-lipid composition and gall-bladder motility) in HTG patients. Design. Randomised cross over. Patients and methods. Gall-bladder motility (ultrasonography) was studied postprandially and during infusion of cholecystokinin (CCK). Determinants of cholelithiasis and serum lipids were compared between 9 HTG patients and 10 age, sex and body-mass index matched normolipidaemic controls. The effects of bezafibrate and purified omega-3-oil ('fish oil') in HTG patients were studied. Results. HTG patients showed 14-fold higher serum-triglyceride (TG) levels than controls. Biliary-lipid composition, fasting gall-bladder volumes, and CCK levels did not differ between HTG patients and controls. Gall-bladder emptying was reduced in HTG patients compared with controls during CCK infusion (-22%) as well as in response to a meal (-37%; both p < 0.001). Postprandial CCK levels were significantly higher in HTG patients. Both bezafibrate and fish oil reduced serum TG levels (-68 and -51% versus baseline, respectively; both p < 0.01). Fasting CCK levels were not affected whereas CCK-induced gall-bladder emptying increased during bezafibrate (+29%; p < 0.001) and tended to increase upon fish-oil therapy (+13%; p = 0.07). Postprandial gall-bladder motility improved at least partly with bezafibrate and fish oil (+47 and +25% versus baseline, respectively; both p < 0.02) due to increased gallbladder sensitivity to CCK (both p < 0.05 versus baseline). Bezafibrate but not fish oil increased the molar ratio of cholesterol to bile acids (+40%; p ≤ 0.05), but no effects on the cholesterol-saturation index were seen with either treatment. Conclusions. We suggest that impaired gall-bladder motility occurs in HTG patients due to decreased sensitivity to CCK, which may add to the enhanced risk of gall-stone disease in HTG patients. Triglyceride-lowering therapy by both fish oil and bezafibrate improves gall-bladder dysmotility without adversely affecting biliary-cholesterol saturation.</p
Gall-bladder dysmotility - A risk factor for gall-stone formation in hypertriglyceridaemia and reversal on triglyceride-lowering therapy with bezafibrate and fish oil
Doel: Onderzoeken van de pathofysiologische mechanismen die de kans op galstenen verhogen bij hypertriglyceridemie (HTG) en het vergelijken van de effecten van triglycerideverlagende therapie met bezafibraat en visolie op determinanten van cholelithiasis (biliaire lipidesamenstelling en galblaasmotoriek) bij HTG-patiënten.Opzet: Gekruiste opzet met ‘random’-volgorde.Patiënten en methoden: De galblaasmotoriek werd postprandiaal en tijdens cholecystokinine(CCK)-infusie echografisch onderzocht. De determinanten van cholelithiasis en de serumlipiden werden vergeleken tussen 9 HTG-patiënten en 10 normolipidemische controlepersonen van hetzelfde geslacht, dezelfde leeftijd en ‘body mass’-index. Bij de HTG-patiënten werden de effecten van bezafibraat en gezuiverde omega-3-olie (‘visolie’) bepaald.Resultaten: De serumtriglyceride(TG)-spiegel van de HTG-patiënten was 14-voudig verhoogd, vergeleken met de controlepersonen. De lipidesamenstelling van de gal, de nuchtere galblaasvolumen en de serum-CCK-spiegels verschilden niet tussen HTG-patiënten en controlepersonen. De galblaaslediging was verminderd bij HTG-patiënten versus controlepersonen tijdens CCK-infusie (–22) en ook na een maaltijd (–37; beide p < 0,001). De postprandiale serum-CCK-spiegels waren significant hoger bij HTG-patiënten. Zowel bezafibraat als visolie verlaagde de serum-TG-spiegel (–68 en –51 ten opzichte van de uitgangswaarde; beide: p < 0,01). Nuchtere CCK-spiegels verschilden niet, terwijl de CCK-geïnduceerde galblaaslediging onder bezafibraat toenam met 29 (p < 0,001) en met visolie met 13 (p = 0,07). De postprandiale galblaasmotoriek verbeterde tijdens zowel bezafibraat- (+47) als visoliebehandeling (+25; beide: p < 0,02), waarschijnlijk gedeeltelijk door een toegenomen gevoeligheid van de galblaas voor CCK (voor beide: p < 0,05 vergeleken met de uitgangsfase). Bezafibraat, in tegenstelling tot visolie, verhoogde de molaire cholesterol-galzuurratio (+40; p ≤ 0,05), terwijl beide behandelingen geen effect hadden op de cholesterolsaturatie-index.Conclusies: De verminderde galblaasmotoriek bij HTG-patiënten lijkt het gevolg te zijn van verminderde gevoeligheid voor CCK, wat kan bijdragen aan het verhoogde risico op galsteenvorming. Bij HTG-patiënten verbetert triglycerideverlagende therapie met visolie of bezafibraat de verminderde galblaasmotoriek zonder nadelig effect op de biliaire cholesterolverzadiging.Objective. To unravel the mechanisms responsible for the increased risk of gall-stone disease in hypertriglyceridaemia (HTG) and to compare the effects of triglyceride-lowering therapy with bezafibrate and fish oil on determinants of cholelithiasis (biliary-lipid composition and gall-bladder motility) in HTG patients. Design. Randomised cross over. Patients and methods. Gall-bladder motility (ultrasonography) was studied postprandially and during infusion of cholecystokinin (CCK). Determinants of cholelithiasis and serum lipids were compared between 9 HTG patients and 10 age, sex and body-mass index matched normolipidaemic controls. The effects of bezafibrate and purified omega-3-oil ('fish oil') in HTG patients were studied. Results. HTG patients showed 14-fold higher serum-triglyceride (TG) levels than controls. Biliary-lipid composition, fasting gall-bladder volumes, and CCK levels did not differ between HTG patients and controls. Gall-bladder emptying was reduced in HTG patients compared with controls during CCK infusion (-22%) as well as in response to a meal (-37%; both p < 0.001). Postprandial CCK levels were significantly higher in HTG patients. Both bezafibrate and fish oil reduced serum TG levels (-68 and -51% versus baseline, respectively; both p < 0.01). Fasting CCK levels were not affected whereas CCK-induced gall-bladder emptying increased during bezafibrate (+29%; p < 0.001) and tended to increase upon fish-oil therapy (+13%; p = 0.07). Postprandial gall-bladder motility improved at least partly with bezafibrate and fish oil (+47 and +25% versus baseline, respectively; both p < 0.02) due to increased gallbladder sensitivity to CCK (both p < 0.05 versus baseline). Bezafibrate but not fish oil increased the molar ratio of cholesterol to bile acids (+40%; p ≤ 0.05), but no effects on the cholesterol-saturation index were seen with either treatment. Conclusions. We suggest that impaired gall-bladder motility occurs in HTG patients due to decreased sensitivity to CCK, which may add to the enhanced risk of gall-stone disease in HTG patients. Triglyceride-lowering therapy by both fish oil and bezafibrate improves gall-bladder dysmotility without adversely affecting biliary-cholesterol saturation.</p
Preliminary fabrication and characterization of electron beam melted Ti–6Al–4V customized dental implant
The current study was aimed to fabricate customized root form dental implant using
additive manufacturing technique for the replacement of missing teeth. The root form dental
implant was designed using GeomagicTM and MagicsTM, the designed implant was directly manufactured
by layering technique using ARCAM A2TM electron beam melting system by employing medical
grade Ti–6Al–4V alloy powder. Furthermore, the fabricated implant was characterized in terms
of certain clinically important parameters such as surface microstructure, surface topography,
chemical purity and internal porosity. Results confirmed that, fabrication of customized dental implants using additive rapid manufacturing technology offers an attractive method to produce
extremely pure form of customized titanium dental implants, the rough and porous surface texture
obtained is expected to provide better initial implant stabilization and superior osseointegration
- …